338 related articles for article (PubMed ID: 9673796)
1. Dynorphin A(1-8): stability and implications for in vitro opioid activity.
Bell KM; Traynor JR
Can J Physiol Pharmacol; 1998 Mar; 76(3):325-33. PubMed ID: 9673796
[TBL] [Abstract][Full Text] [Related]
2. Opioid profiles of Cys2-containing enkephalin analogues.
Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
5. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
[TBL] [Abstract][Full Text] [Related]
6. Receptor preference of dynorphin A fragments in the mouse vas deferens determined by different techniques.
Schulz R; Wüster M; Herz A
J Pharmacol Exp Ther; 1984 Jul; 230(1):200-4. PubMed ID: 6146706
[TBL] [Abstract][Full Text] [Related]
7. Characterization of kappa and delta opioid receptors in isolated organs by using type/subtype selective agonists and antagonists.
Makó E; Rónai AZ
Med Sci Monit; 2001; 7(3):350-6. PubMed ID: 11386008
[TBL] [Abstract][Full Text] [Related]
8. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
9. Protection against dynorphin-(1-8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon.
Hiranuma T; Kitamura K; Taniguchi T; Kanai M; Arai Y; Iwao K; Oka T
J Pharmacol Exp Ther; 1998 Aug; 286(2):863-9. PubMed ID: 9694943
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
11. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands.
Kramer TH; Davis P; Hruby VJ; Burks TF; Porreca F
J Pharmacol Exp Ther; 1993 Aug; 266(2):577-84. PubMed ID: 8394911
[TBL] [Abstract][Full Text] [Related]
12. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
13. Irreversible blockade of the kappa-receptor by a newly synthesized dynorphin derivative containing a 3-nitro-2-pyridinesulfenyl group.
Koike K; Takayanagi I; Hirakura Y; Matsueda R
Arch Int Pharmacodyn Ther; 1991; 313():33-46. PubMed ID: 1687773
[TBL] [Abstract][Full Text] [Related]
14. The choice of opioid receptor subtype in isolated preparations by dynorphins.
Oka T; Aoki K; Kajiwara M
Life Sci; 1983; 33 Suppl 1():311-4. PubMed ID: 6141492
[TBL] [Abstract][Full Text] [Related]
15. Evidence that the agonist action of dynorphin A(1-8) in the guinea-pig myenteric-plexus may be mediated partly through conversion to [Leu5]enkephalin.
Dixon DM; Traynor JR
Br J Pharmacol; 1990 Nov; 101(3):674-8. PubMed ID: 1981690
[TBL] [Abstract][Full Text] [Related]
16. A novel phencyclidine analog interacts selectively with mu opioid receptors.
Itzhak Y; Simon EJ
J Pharmacol Exp Ther; 1984 Aug; 230(2):383-6. PubMed ID: 6086884
[TBL] [Abstract][Full Text] [Related]
17. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
20. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
